Navigation Links
Hyperviscous fluids: Better treatment for severe blood loss
Date:4/28/2008

Intravenous administration of isotonic fluids is the standard emergency treatment in the U.S. for patients with severe blood loss, but UC San Diego bioengineering researchers have reported improved resuscitation with a radically different approach. Building on earlier studies in humans that have shown benefits of intravenous fluids that are eight times saltier than normal saline, the researchers combined hypertonic saline with viscosity enhancers that thicken blood.

Reporting in the journal Resuscitation in an article that is available online, the researchers describe dramatic increases in beneficial blood flows in the small blood vessels of hamsters with the combined hypertonic saline and viscosity enhancement approach. The fluid was given to animals after as much as half of their blood was removed to simulate human blood losses on the battlefield, in traffic accidents and in operating rooms.

The team led by Marcos Intaglietta, a professor of bioengineering at the Jacobs School of Engineering, reported that the new approach sharply improved the animals functional capillary density, a key measure of healthy blood flow through tissues and organs.

Of course, trauma physicians want to get the blood flowing as soon as possible, and increasing the viscosity of blood may not make any sense to them, said Intaglietta. However, our results are highly suggestive that increasing viscosity rather and partially restoring blood volume is a better way to increase blood flow through tissues. These findings also are consistent with recent discoveries showing that higher shear forces of more viscous blood leads to dilation of small blood vessels.

Treating blood loss is a critical medical issue because trauma is the leading cause of death among North Americans 1 to 44 years old. Whether injured on the freeway or wounded in battlefield, loss of 40 percent or more of a patients blood is immediately life-threatening. Physicians and emergenc
'/>"/>

Contact: Rex Graham
ragraham@ucsd.edu
858-822-3075
University of California - San Diego
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
2. How and where fat is stored predicts disease risk better than weight
3. Continuous oral contraceptives better at easing pain, bleeding
4. David H. Ledbetter, PhD, FACMG is the 2008-2009 Luminex/ACMGF Award recipient
5. Ant guts could pave the way for better drugs
6. Newly defined signaling pathway could mean better biofuel sources
7. Analysis calls for medical device information to better serve patients and doctors
8. Better protection for biomedial devices could result from Rutgers-Camden research
9. Researchers develop better membranes for water treatment, drug delivery
10. Marine scientists warn human safety, prosperity depend on better ocean observing system
11. Human safety, prosperity depend on better ocean observing system: Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hyperviscous fluids: Better treatment for severe blood loss
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... of new coal-fired power plants in the United States ... due to the high cost of the requirement ... of carbon dioxide, an important greenhouse gas. But an ... construction moving again, allowing the nation to fend off ...
... by researchers at UC Davis Medical Center suggests that ... be a result of their brains not telling their ... blood oxygen levels are more common than we thought ... Masud Seyal, a professor of neurology at UC Davis ...
... , Thanks to our ability to learn and to remember, we ... of. However, we are only just beginning to get the gist ... or forgets something. What we do know is that changes in ... these structural changes account for that well-known phenomenon that it is ...
Cached Biology News:MIT: A quicker, easier way to make coal cleaner 2MIT: A quicker, easier way to make coal cleaner 3Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 2Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 3Forgotten but not gone -- how the brain takes care of things 2Forgotten but not gone -- how the brain takes care of things 3
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. This report briefly ... sequencing technologies, and their applications. Current large and ... developing them. Various applications of sequencing are described ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... their offering. The markets for gene therapy ... approved gene therapy product and it is marketed in ... markets are estimated for the years 2014-2024. The estimates ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... BioLight Life Sciences Investments ... a firm that invests in, manages and commercializes ... today that presentations highlighting its IOPtiMate™ system for ... the Ophthalmology Futures European Forum and the XXXIII ... Refractive Surgeons ("ESCRS"), both taking place in the ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today ... ended December 31, 2008."2008 was a transition year for ... focused on lower-risk reformulations of previously-approved drugs. We achieved ... the difficult economic environment, we were unable to attract ...
... Insmed Inc. (Nasdaq: INSM ), a developer of ... March 23, 2009, NASDAQ issued a notice further extending the ... price and those rules requiring a minimum market value of ... effect through Friday, July 17, 2009, and the original rules ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... patient enrolment in its U.K. clinical trial to ... REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients ... neck. The principal investigators are Dr. Johann de ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
... The wide mini ReadySub-Cell GT cell and ... horizontal gel electrophoresis of nucleic acids in agarose ... buffer tank, lid with cables and electrodes, and ... and 220-240 V, provides output of 10-300 V, ...
... and you reduce the chance of error. ... 8000. Developed using Beckman Coulters extensive experience ... electrophoresis technology, the CEQ 8000 is a ... automatically fills the capillary array with a ...
... 2000 Capillary Electrophoresis System uses revolutionary ... electrophoresis (SPE), urine protein electrophoresis and ... accurate analysis. The system is truly ... and no staining to process patient ...
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
Biology Products: